Myositis International Health & Research Collaborative Alliance
The Myositis International Health and Research Collaborative Alliance (MIHRA) Foundation is a 501(c)(3) non-profit charitable research organization was founded ‘BY THE MYOSIITIS COMMUNITY, FOR THE MYOSITIS COMMUNITY’ to ‘create a world where we cure myositis together’.
MIHRA is a movement, an engine and infrastructure dedicated toward safeguarding sustainability in highly collaborative research and preservation of the authentic scientific and patient voice of the research community. Founded and operated by cross-disciplinary scientists, patient leaders, and partner organizations, the MIHRA community drives high-impact research to overcome the barriers to clinical trial readiness and worldwide excellence in clinical care and mentorship securing the future for myositis research.
MIHRA Foundation: Creating a World Where We Cure Myositis Together.
MIHRA Foundation: The Collective Voice of the Research Community
Founded by the Research Community for the Research Community
MIHRA Foundation: The First Rare Disease to Partner with the FDA CDER to Solve Critical Barriers to Clinical Trial Readiness in Myositis Diseases
MIHRA Foundation: Where Altruism Meets Trusted, Dependable Science in Myositis Diseases
MIHRA – pronounced mee-rah – across the globe has roots in meanings such as goodness, kindness, community, communal governance & peace. Meanings that perfectly reflect 25 Years of international research community efforts in myositis.
Join us at Booth #2001
- Come have conversations about your tough myositis cases with experts in the field! Check the ACR Convergence App for schedule!! Or here https://mihrafoundation.org/join-mihra-at-the-american-college-of-rheumatology/ !!!
- Learn about MIHRA’s FDA CDER PPP and What it means for you
- Enquire about the 2026 MIHRA GCOM Fellowships
MIHRA is honored to be the first rare disease to partner with the U.S. Food and Drug Administration (FDA) through its Center for Drug Evaluation and Research (CDER) in a public–private partnership (PPP) to address the critical barriers in clinical trial design in myositis diseases. Together patient leaders, scientific experts, partner organizations, industry partners and government agencies, MIHRA will be a vehicle to accelerate therapeutic breakthroughs and stabilize the clinical trial landscape that no single person or group could do alone.
In MIHRA patients are equal partners and leaders in governance and advancing the field. MIHRA is committed to patient-initiated and patient-driven scientific endeavors and patients are embedded in every aspect of MIHRA’s governance, mission development and research.
MIHRA Flagship programming:
• *Myositis University: fully accredited, cost-free, cross-disciplinary education to help generalists and specialists recognize IIM earlier, treat appropriately, and implement research-grade assessments in clinic.
• Clinical Trials Site Network (CTSN): practical mentorship and feasibility mapping that readies new and established sites, standardizes operations and outcome implementation, and strengthens recruitment quality and speed.
• MIHRA IIM Specialty Clinics (ISC) listings and MIHRA Current Clinical Studies Listings (CCS): tools for patients, caregivers, and clinicians to quickly find expertise and active studies.
• *MIHRA Board Review Question Bank (public access): a growing, open resource to strengthen foundational IIM knowledge and standardize learning across disciplines.
*= Launching soon – will be announced in the newsletter!